Vilazodone
(Redirected from Viibryd)
Vilazodone[edit | edit source]
Vilazodone is a pharmacological compound primarily recognized as a selective serotonin reuptake inhibitor (SSRI) with added properties as a partial serotonin receptor agonist. It is most commonly prescribed for the treatment of major depressive disorders.
Liver Safety[edit | edit source]
Extensive scrutiny into the safety of Vilazodone, particularly concerning the liver, has been undertaken. In studies conducted prior to its commercial release, vilazodone therapy was not correlated with a rise in serum aminotransferase levels, a common marker for liver health. Moreover, there is no evidence currently linking vilazodone to instances of clinically significant acute liver injury.
Mechanism of Action[edit | edit source]
Vilazodone operates predominantly as an SSRI, targeting the synaptic clefts in the Central Nervous System (CNS). By inhibiting the reuptake of serotonin, it results in elevated levels of this neurotransmitter in the brain, which is believed to be associated with its psychiatric benefits. Additionally, as a partial serotonin (5-HT1A) receptor agonist, vilazodone possibly enhances its antidepressant capabilities.
FDA Approval[edit | edit source]
The U.S. Food and Drug Administration (FDA) granted approval for the use of Vilazodone in the treatment of major depressive disorder in 2011. However, it's noteworthy that the clinical experience with vilazodone remains relatively limited compared to other SSRIs.
Brand Name[edit | edit source]
Vilazodone can be procured in the pharmaceutical market under the brand name Viibryd. It is accessible in tablet form in concentrations of 10, 20, and 40 mg.
Dosage and Administration[edit | edit source]
For adults initiating vilazodone therapy, a starting dose of 10 mg daily is recommended. Depending on the individual's response and tolerance, this can subsequently be escalated to a standard maintenance dose of 40 mg taken once daily.
Side Effects[edit | edit source]
Like all therapeutic compounds, vilazodone comes with potential side effects. Common and relatively benign symptoms reported include:
- Diarrhea
- Nausea
- Fatigue
- Drowsiness
- Headache
- Insomnia
- Weight gain
- Sexual dysfunction
In cases of overdose, patients may exhibit symptoms of the acute serotonin syndrome. Rarer, yet more severe potential adverse reactions encompass:
- Suicidal ideation and behavior
- Activation of manic symptoms
- Prolonged sexual dysfunction
- Hyponatremia
- Severe hypersensitivity reactions
See Also[edit | edit source]
The following are antidepressant subclasses and drugs
MAO Inhibitors Isocarboxazid, Phenelzine, Tranylcypromine
SNRIs Duloxetine, Levomilnacipran, Venlafaxine
SSRIs Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Vortioxetine
Tricyclics Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline, Trimipramine
Miscellaneous Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone
Vilazodone Resources | ||
---|---|---|
|
|
Vilazodone Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD